The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
April 23rd 2024
The FDA granted accelerated approval to talquetamab on August 9, 2023, as a treatment option for adult patients with relapsed/refractory multiple myeloma (RRMM) who have failed at least 4 prior lines of therapy.
More Early Palliative Care May Be Needed to Individualize Pain Management in MM
March 4th 2022Investigators concluded that early palliative care may be needed for more patients with multiple myeloma (MM) as pain can manifest in different ways and severity levels depending on disease state, suggesting that a more individualized approach is critical for pain management.
Read More
Study on Types of Pain in MM Reveals Communication Inadequacies Between Physicians, Patients
February 28th 2022A study showed that patients with multiple myeloma (MM) deal with physical, social, and emotional pain and that physicians did not fully comprehend the extent to which patients experienced pain, suggesting improved communication between parties is warranted.
Read More
Study Highlights Unmet Exercise Needs Among Patients With MM
February 25th 2022Health care providers need to foster a greater push for physical activity as a part of survivorship care for patients with multiple myeloma (MM), investigators concluded after finding that only 25% of patients were active.
Read More
Review Outlines Unmet Need for Digital Health in Elderly Patients With MM
February 22nd 2022Access to digital health tools to improve patient outcomes and quality of life are lacking among patients with multiple myeloma (MM) who are elderly, at risk of relapse, or live in rural communities, suggesting more tools and guidelines are needed for these populations.
Read More
Clinical, Economic Burden of Corneal Adverse Events in MM Is Low Compared With Total All-Cause Costs
February 9th 2022Researchers concluded that incident corneal adverse events in patients with multiple myeloma (MM) carry a low clinical and economic burden compared with total all-cause costs and MM-related per-patient-per-month costs.
Read More
COVID-19 Led to Delayed Diagnoses, Increased Infection Risk, Lower Survival Rates in MM
February 1st 2022A large international real-world analysis revealed the extent to which the COVID-19 pandemic has impacted the global population of patients with multiple myeloma (MM) and the ability for providers to help patients manage the condition.
Read More
Study: Adrenal Insufficiency Found in Some MM Patients on Corticosteroid-Based Chemotherapy
January 28th 2022About half of all patients with multiple myeloma (MM) receiving corticosteroid-based chemotherapy were found to have adrenal insufficiency (AI), while identifying suspicious symptoms of AI may be a key component to its detection in this population.
Read More
Interview: Real-World Data Show Daratumumab 1L Improves OS in Some Patients With MM
January 11th 2022For patients with multiple myeloma (MM) who are not eligible for transplant, should novel treatments be used right away? Or should clinicians save the best potential therapies for relapses, which are inevitable with this disease?
Read More
Dr Robert Rifkin Explains the Importance of Real-world Data in MM Patient Populations
December 20th 2021Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, describes his research on real-world treatment patterns among patients with triple-class refractory multiple myeloma.
Watch